The single-nucleotide polymorphisms in CHD5 affect the prognosis of patients with hepatocellular carcinoma
- PMID: 29568352
- PMCID: PMC5862573
- DOI: 10.18632/oncotarget.23812
The single-nucleotide polymorphisms in CHD5 affect the prognosis of patients with hepatocellular carcinoma
Abstract
Previous studies showed that the low expressions of chromodomain-helicase-DNA-binding protein 5 (CHD5) were intensively associated with deteriorative biologic and clinical characteristics as well as outcomes in many tumors. The aim of this study is to determine whether CHD5 single nucleotide polymorphisms (SNPs) contribute to the prognosis of hepatocellular carcima (HCC). The SNPs were selected according to their linkage disequilibrium (LD) in the targeted next-generation sequencing (NGS) and then genotyped with TaqMan probers. We revealed a rare haplotype AG in CHD5 (SNPs: rs12564469-rs9434711) was markedly associated with HCC prognosis. The univariate and multivariate regression analyses revealed the patients with worse overall survival time were those with tumor metastasis and haplotype AG, as well as cirrhosis, poor differentiation and IV-TNM stage. Based on the available public databases, we discovered the significant association between haplotype AG and CHD5 mRNA expressions only existed in Chinese. These data proposed that the potentially genetic haplotype might functionally contribute to HCC prognosis and CHD5 mRNA expressions.
Keywords: chromodomain-helicase-DNA-binding protein 5; hepatocellular carcinoma; linkage disequilibrium; prognosis; single-nucleotide polymorphisms.
Conflict of interest statement
CONFLICTS OF INTEREST The authors have no conflicts of interest to declare.
Figures



Similar articles
-
A rare CHD5 haplotype and its interactions with environmental factors predicting hepatocellular carcinoma risk.BMC Cancer. 2018 Jun 15;18(1):658. doi: 10.1186/s12885-018-4551-y. BMC Cancer. 2018. PMID: 29907144 Free PMC article.
-
CHD5 a tumour suppressor is epigenetically silenced in hepatocellular carcinoma.Liver Int. 2014 Jul;34(6):e151-60. doi: 10.1111/liv.12503. Epub 2014 Mar 15. Liver Int. 2014. PMID: 24529164
-
Genetic variations in chromodomain helicase DNA-binding protein 5, gene-environment interactions and risk of sporadic Alzheimer's disease in Chinese population.Oncotarget. 2018 May 18;9(38):24872-24881. doi: 10.18632/oncotarget.23791. eCollection 2018 May 18. Oncotarget. 2018. PMID: 29861839 Free PMC article.
-
Expression of CHD5 may serve as an independent biomarker of prognosis in colorectal cancer via immunohistochemical staining.Int J Clin Exp Pathol. 2018 May 1;11(5):2792-2798. eCollection 2018. Int J Clin Exp Pathol. 2018. PMID: 31938397 Free PMC article.
-
Role of CHD5 in human cancers: 10 years later.Cancer Res. 2014 Feb 1;74(3):652-8. doi: 10.1158/0008-5472.CAN-13-3056. Epub 2014 Jan 13. Cancer Res. 2014. PMID: 24419087 Free PMC article. Review.
Cited by
-
Clinical value of circulating tumor cells for the diagnosis and prognosis of hepatocellular carcinoma (HCC): A systematic review and meta-analysis.Medicine (Baltimore). 2020 Oct 2;99(40):e22242. doi: 10.1097/MD.0000000000022242. Medicine (Baltimore). 2020. PMID: 33019399 Free PMC article.
-
Pathway analysis of smoking-induced changes in buccal mucosal gene expression.Egypt J Med Hum Genet. 2022;23(1):69. doi: 10.1186/s43042-022-00268-y. Epub 2022 Mar 17. Egypt J Med Hum Genet. 2022. PMID: 37521848 Free PMC article.
-
A rare CHD5 haplotype and its interactions with environmental factors predicting hepatocellular carcinoma risk.BMC Cancer. 2018 Jun 15;18(1):658. doi: 10.1186/s12885-018-4551-y. BMC Cancer. 2018. PMID: 29907144 Free PMC article.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. - PubMed
-
- Mallette FA, Richard S. JMJD2A Promotes Cellular Transformation by Blocking Cellular Senescence through Transcriptional Repression of the Tumor Suppressor CHD5. Cell reports. 2012;2:1233–1243. - PubMed
-
- Schuster EF, Stoger R. CHD5 defines a new subfamily of chromodomain-SWI2/SNF2-like helicases. Mamm Genome. 2002;13:117–119. - PubMed
-
- Du Z, Li L, Huang X, Jin J, Huang S, Zhang Q, Tao Q. The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation. Oncotarget. 2016;7:21618–21630. https://doi.org/10.18632/oncotarget.7822. - DOI - PMC - PubMed
-
- Naraparaju K, Kolla V, Zhuang T, Higashi M, Iyer R, Kolla S, Okawa ER, Blobel GA, Brodeur GM. Role of microRNAs in epigenetic silencing of the CHD5 tumor suppressor gene in neuroblastomas. Oncotarget. 2016;7:15977–15985. https://doi.org/10.18632/oncotarget.7434. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials